Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Investment analysts at SunTrust Banks cut their FY2020 earnings per share estimates for shares of Endo International in a research note issued on Monday, August 12th. SunTrust Banks analyst G. Gilbert now expects that the company will post earnings of $2.50 per share for the year, down from their previous forecast of $2.53. SunTrust Banks also issued estimates for Endo International’s FY2021 earnings at $2.23 EPS and FY2023 earnings at $1.56 EPS.
Several other research firms have also recently weighed in on ENDP. BidaskClub cut Endo International from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 18th. Morgan Stanley set a $2.00 price objective on Endo International and gave the company a “sell” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. cut Endo International from a “neutral” rating to an “underweight” rating and set a $9.00 price objective for the company. in a research report on Monday, May 13th. Cantor Fitzgerald reduced their price objective on Endo International from $18.00 to $4.75 and set a “neutral” rating for the company in a research report on Wednesday, June 12th. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $6.00 price objective on shares of Endo International in a research report on Thursday, August 8th. Four research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have assigned a buy rating to the company’s stock. Endo International has an average rating of “Hold” and an average target price of $8.48.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Endo International had a negative return on equity of 129.30% and a negative net margin of 19.98%. The company had revenue of $699.71 million during the quarter, compared to analysts’ expectations of $694.60 million. During the same period in the prior year, the business earned $0.76 earnings per share. Endo International’s revenue for the quarter was down 2.1% compared to the same quarter last year.
In related news, Director Roger H. Kimmel sold 34,951 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $3.93, for a total value of $137,357.43. Following the completion of the transaction, the director now directly owns 148,309 shares of the company’s stock, valued at $582,854.37. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.50% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the stock. Paloma Partners Management Co bought a new position in Endo International in the second quarter worth $98,000. Signition LP bought a new position in Endo International in the first quarter worth $139,000. Meeder Asset Management Inc. lifted its position in Endo International by 47.1% in the second quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock worth $156,000 after purchasing an additional 12,127 shares during the period. Factorial Partners LLC bought a new position in Endo International in the first quarter worth $193,000. Finally, First Quadrant L P CA lifted its position in Endo International by 94.7% in the first quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock worth $197,000 after purchasing an additional 11,926 shares during the period. 93.37% of the stock is owned by hedge funds and other institutional investors.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.